Pramod K Gupta, Age 515105 S Harper Ave UNIT 1306, Chicago, IL 60615

2002019, Dec 19, 2002

Dec 26, 2001

10/036129

Rajneesh Taneja - Libertyville IL, US
Pramod Gupta - Gurnee IL, US

A61K031/4439
A61K033/00

424/717000, 514/338000

A method for treating gastric acid disorders with a non-enteric coated proton pump inhibitor in a pharmaceutically acceptable carrier including a bicarbonate salt of a Group IA metal and a carbonate salt of a Group IA metal; and a pharmaceutical composition of a non-enteric coated proton pump inhibitor in a pharmaceutically acceptable carrier including a bicarbonate salt of a Group IA metal and a carbonate salt of a Group IA metal are disclosed. A presently preferred proton pump inhibitor is lansoprazole, a presently preferred bicarbonate salt is sodium bicarbonate, and a presently preferred carbonate salt is sodium carbonate. The composition is a fast-acting formulation which reduces the undesirable belching associated with proton pump inhibitor formulations that contain high doses of sodium bicarbonate.

2003006, Mar 27, 2003

May 28, 2002

10/156488

Rajneesh Taneja - Libertyville IL, US
Dale Brinker - Antioch IL, US
Jacqueline Briskin - Buffalo Grove IL, US
Dilip Vishwasrao - Waukegan IL, US
Roberto Aponte - Grayslake IL, US
Pramod Gupta - Gurnee IL, US

A61K031/685
A61K031/56
A61K031/545

514/078000, 514/200000, 514/171000

A method for enhancing the oral bioavailability of a prodrug ester by formulating the ester as a non-emulsified formulation with lecithin; as well as a pharmaceutical composition of at least one antibiotic and lecithin in a non-emulsified formulation; a method of treating infections with the non-emulsified formulation, and a method for preparing tablets by direct compression of blends of drugs with lecithin are disclosed. Non-emulsified formulations include solids, tablets, capsules, lozenges, suspensions, elixirs and solutions, and exclude emulsions, liposomes, lipid matrix systems and micro-emulsions. A suitable prodrug ester is a cephalosporin -lactam antibiotic such as cefditoren pivoxil, and a suitable non-emulsified formulation is a solid formulation.

2003016, Sep 4, 2003

Dec 18, 2002

10/322988

Rajneesh Taneja - Libertyville IL, US
Pramod Gupta - Gurnee IL, US

G07F011/00

221/076000

The present invention relates to a package system intended to simplify the usage of multiple medications stored separately and used together, thereby minimize the non-compliant use of the multiple medications. Generally, the separate medication components are contained in a plurality of cavities, arranged in one or more arcs or concentric circles. The package system further includes an access shield having one or more openings, which are selectively aligned in one of a plurality of positions, corresponding to the per use groupings. When the one or more openings in an access shield are aligned with the cavities corresponding to one of the per use groupings, the medication components are capable of being released from their respective cavities. Conversely, the shield substantially restricts access to the medication components located in the non-aligned cavities.

2003023, Dec 25, 2003

Sep 19, 2001

09/955801

Rajneesh Taneja - Libertyville IL, US
Pramod Gupta - Gurnee IL, US

A61K033/10
A61K033/00
A61K033/08
A01N033/02
A61K031/13
A61K031/4439

424/687000, 424/690000, 424/692000, 424/715000, 424/717000, 514/338000, 514/663000

Methods and pharmaceutical compositions for protecting pharmaceutical compounds (or drugs) in acidic environments are provided. Methods of treatment using formulations capable of protecting pharmaceutical compounds in acidic environments are also provided. Formulations provided generally comprise a therapeutically effective amount of at least one pharmaceutical compound, and a pharmaceutically acceptable protectant. The pharmaceutically acceptable protectant of the invention generally comprises a water-soluble acid neutralizer, and a water-insoluble acid neutralizer.

2005011, May 26, 2005

Dec 13, 2004

11/014798

Rajneesh Taneja - Libertyville IL, US
Dale Brinker - Antioch IL, US
Jacqueline Briskin - Buffalo Grove IL, US
Dilip Vishwasrao - Waukegan IL, US
Roberto Aponte - Grayslake IL, US
Pramod Gupta - Gurnee IL, US

A61K031/685
A61K031/545
A61K031/57

514078000, 514200000, 514171000

A method for enhancing the oral bioavailability of a prodrug ester by formulating the ester as a non-emulsified formulation with lecithin; as well as a pharmaceutical composition of at least one antibiotic and lecithin in a non-emulsified formulation; a method of treating infections with the non-emulsified formulation, and a method for preparing tablets by direct compression of blends of drugs with lecithin are disclosed. Non-emulsified formulations include solids, tablets, capsules, lozenges, suspensions, elixirs and solutions, and exclude emulsions, liposomes, lipid matrix systems and micro-emulsions. A suitable prodrug ester is a cephalosporin β-lactam antibiotic such as cefditoren pivoxil, and a suitable non-emulsified formulation is a solid formulation.

2006028, Dec 14, 2006

Jun 12, 2006

11/423491

Barrett Rabinow - Skokie IL, US
Chyung Cook - Northbrook IL, US
Pramod Gupta - Pittsford NY, US

A61K 9/127
A61K 9/14

424450000, 424489000, 977906000

A pharmaceutical combination for minimizing pharmacokinetic drug-drug interaction is described including a first pharmaceutical component having a particular pharmacokinetic profile in a mammal and a second pharmaceutical component formulated for parenteral administration having an altered pharmacokinetic profile different from the unaltered pharmacokinetic profile of the second pharmaceutical component, which would interfere with the pharmacokinetic profile of the first pharmaceutical component. Due to its altered pharmacokinetic profile, the second pharmaceutical component does not substantially affect the pharmacokinetic profile of the first pharmaceutical component.

2009022, Sep 3, 2009

May 12, 2009

12/464847

Rajneesh Taneja - Libertyville IL, US
Pramod Gupta - Gurnee IL, US

A61K 33/10
A61P 1/04

424717, 424715

A method for treating gastric acid disorders with a non-enteric coated proton pump inhibitor in a pharmaceutically acceptable carrier including a bicarbonate salt of a Group IA metal and a carbonate salt of a Group IA metal; and a pharmaceutical composition of a non-enteric coated proton pump inhibitor in a pharmaceutically acceptable carrier including a bicarbonate salt of a Group IA metal and a carbonate salt of a Group IA metal are disclosed. A presently preferred proton pump inhibitor is lansoprazole, a presently preferred bicarbonate salt is sodium bicarbonate, and a presently preferred carbonate salt is sodium carbonate. The composition is a fast-acting formulation which reduces the undesirable belching associated with proton pump inhibitor formulations that contain high doses of sodium bicarbonate.

2011018, Jul 28, 2011

Dec 28, 2010

12/979486

Rajneesh Taneja - Libertyville IL, US
Pramod Gupta - Pittsford NY, US

A61J 1/03
B65D 83/04

206531, 206534

The present invention relates to a packaging system intended to simplify the usage of multiple medications stored separately and used together, thereby minimize the non-compliant use of the multiple medications. Generally, the separate medications are grouped together on a per dose basis in a plurality of blister pack recesses. A single cover sheet is used to commonly seal the related medications to be used together, such that when the corresponding cover sheet is removed the multiple medications are commonly accessed.